CRISPR Therapeutics AG (CRSP) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 13.78
30Y Low13.8·High50.1
P/FCF
N/A
—
5yr avg: 13.32
30Y Low13.3·High69.4
P/B Ratio
↓
2.58
+17% vs avg
5yr avg: 2.21
30Y Low1.1·High6.1
ROE
↓
-30.2%
↑-117% vs avg
5yr avg: -13.9%
30Y Low-57%·High19%
Debt/EBITDA
N/A
—
5yr avg: 0.57
30Y Low0.6·High1.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRSP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CRISPR Therapeutics AG currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.3B | $4.7B | $3.3B | $5.0B | $3.2B | $6.1B | $10.1B | $3.5B | $1.4B | $941M | $248M |
| Enterprise Value | $5.4B | $4.8B | $3.2B | $4.8B | $3.2B | $5.4B | $9.0B | $2.6B | $914M | $701M | $-67183394 |
| P/E Ratio → | -8.51 | — | — | — | — | 16.12 | — | 52.06 | — | — | — |
| P/S Ratio | 1513.50 | 1343.50 | 94.87 | 13.40 | 7248.62 | 6.67 | 14043.89 | 11.97 | 438.65 | 22.94 | 48.09 |
| P/B Ratio | 2.58 | 2.45 | 1.72 | 2.63 | 1.69 | 2.54 | 6.07 | 3.69 | 3.49 | 5.01 | 1.07 |
| P/FCF | — | — | — | — | — | 13.32 | — | 69.36 | — | — | — |
| P/OCF | — | — | — | — | — | 11.30 | — | 61.18 | — | — | — |
P/E links to full P/E history page with 30-year chart
CRSP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1354.81 | 92.74 | 13.00 | 7322.33 | 5.91 | 12503.98 | 8.90 | 292.48 | 17.09 | -13.01 |
| EV / EBITDA | — | — | — | — | — | 13.78 | — | 50.06 | — | — | — |
| EV / EBIT | — | — | — | — | — | 14.44 | — | 55.12 | — | — | — |
| EV / FCF | — | — | — | — | — | 11.80 | — | 51.53 | — | — | — |
CRSP Profitability
Margins and return-on-capital ratios measuring operating efficiency
CRISPR Therapeutics AG earns an operating margin of -16191.4%. Operating margins have compressed from -60.1% to -16191.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -30.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -6537.0% | -6537.0% | -215.0% | 64.8% | -25186.7% | 88.9% | -37369.7% | 38.1% | -3541.9% | -70.3% | -717.9% |
| Operating Margin | -16191.4% | -16191.4% | -1333.0% | -60.1% | -154394.7% | 40.9% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% |
| Net Profit Margin | -16569.8% | -16569.8% | -1046.4% | -41.5% | -149122.7% | 41.4% | -48520.9% | 23.1% | -5281.1% | -166.7% | -449.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | -19.2% | -8.2% | -30.4% | 18.6% | -26.8% | 10.0% | -56.9% | -32.5% | -22.8% |
| ROA | -25.8% | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% |
| ROIC | -22.3% | -22.3% | -19.5% | -9.2% | -28.0% | 24.8% | -87.8% | 72.7% | — | — | — |
| ROCE | -26.6% | -26.6% | -21.8% | -10.5% | -28.3% | 17.1% | -25.8% | 6.4% | -44.3% | -22.3% | -28.9% |
CRSP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $40M ($395M total debt minus $355M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.57 | — | 1.02 | — | — | — |
| Net Debt / Equity | — | 0.02 | -0.04 | -0.08 | 0.02 | -0.29 | -0.67 | -0.95 | -1.16 | -1.28 | -1.36 |
| Net Debt / EBITDA | — | — | — | — | — | -1.78 | — | -17.32 | — | — | — |
| Debt / FCF | — | — | — | — | — | -1.53 | — | -17.83 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -1.82 |
CRSP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CRISPR Therapeutics AG's current ratio of 13.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.54x to 13.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Quick Ratio | 13.32 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Cash Ratio | 13.30 | 13.30 | 21.69 | 15.57 | 14.99 | 19.85 | 17.93 | 16.53 | 16.46 | 16.52 | 14.34 |
| Asset Turnover | — | 0.00 | 0.02 | 0.17 | 0.00 | 0.33 | 0.00 | 0.27 | 0.01 | 0.15 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 260.71 | 197.30 | — | 0.12 | 5504.95 | 0.12 | 10.28 | 23.38 | 223.14 |
CRSP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CRISPR Therapeutics AG does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 6.2% | — | 1.9% | — | — | — |
| FCF Yield | — | — | — | — | — | 7.5% | — | 1.4% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $90M | $84M | $79M | $78M | $80M | $66M | $57M | $48M | $40M | $12M |
Peer Comparison
Compare CRSP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRSPYou | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $38M | -0.4 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 PRME | $616M | -2.5 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 VRTX | $109B | 27.9 | 21.7 | 34.1 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ILMN | $22B | 26.2 | 20.1 | 23.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 PACB | $516M | -1.6 | — | — | 24.2% | -308.0% | -51.3% | -27.6% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRSP vs EDIT
Side-by-side business, growth, and profitability comparison vs Editas Medicine, Inc..
Start ComparisonCRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
What is CRISPR Therapeutics AG's P/E ratio?
CRISPR Therapeutics AG's current P/E ratio is -8.5x. The historical average is 34.1x.
What is CRISPR Therapeutics AG's ROE?
CRISPR Therapeutics AG's return on equity (ROE) is -30.2%. The historical average is -19.8%.
Is CRSP stock overvalued?
Based on historical data, CRISPR Therapeutics AG is trading at a P/E of -8.5x. Compare with industry peers and growth rates for a complete picture.
What are CRISPR Therapeutics AG's profit margins?
CRISPR Therapeutics AG has -6537.0% gross margin and -16191.4% operating margin.